We are live on ! Find out more
BTTX

Better Therapeutics, Inc. Common Stock

Delisted

BTTX was delisted on the 15th of March, 2024.

27 hedge funds and large institutions have $32.9M invested in Better Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

4% more funds holding

Funds holding: 2627 (+1)

20% less capital invested

Capital invested by funds: $40.9M → $32.9M (-$8.03M)

Holders
27
Holders Change
+1
Holders Change %
+3.85%
% of All Funds
0.47%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
6
Reduced
5
Closed
8
Calls
Puts
Net Calls
Net Calls Change

BTTX Hedge Fund Activity: Q3 2021 in Review

27 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q3 2021, worth a combined $32.9M — down 20% from $40.9M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new BTTX positions and 8 closed out — a net gain of 1 holder — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Sectoral Asset Management, opening a new position worth an estimated $4.64M. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $4.25M sold.

  • 27 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q3 2021, up from 26 in Q2 2021.
  • Funds reported $32.9M of Better Therapeutics, Inc. Common Stock stock for Q3 2021, down 20% quarter-over-quarter.
  • 9 funds opened new Better Therapeutics, Inc. Common Stock positions in Q3 2021 and 8 closed out, a net change of +1 holder.
  • The largest Better Therapeutics, Inc. Common Stock buyer in Q3 2021 was Sectoral Asset Management, an estimated $4.64M added.
  • The largest Better Therapeutics, Inc. Common Stock seller in Q3 2021 was Boothbay Fund Management, an estimated $4.25M sold.

Based on aggregated 13F filings for Q3 2021.